Table 1.

Baseline (first calendar quarter) data of 58,058 MHD patients (July 2001 to June 2003), including 37,049 patients from the first quarter (q1) and 21,009 patients from subsequent quarters (q2 to q8)a

VariableReceived ESA during the Baseline Quarter (n = 53,972)Did not Receive ESA during the Baseline Quarter (n = 4,086)
Age (yr)61 ± 1558 ± 16
Gender (% women)4740
Diabetes (%)4540
Race/ethnicity (%)
    white3648
    blacks3323
    Hispanic1815
Vintage (time on dialysis; %)
    3–6 mo4231
    6–24 mob2220
    2–5 yr2432
    ≥5 yr1317
Patients with a catheter (versus AV shunt)2223
Primary insurance
    Medicare (%)c6060
Known causes of death
    cardiovascular (% of all-cause)5242
    infectious (% of all-cause)b119
Standardized mortality ratioc0.80 ± 0.220.80 ± 0.22
Cohort time (d)467 (268)518 (205)
Body mass index (kg/m2)26.1 ± 6.126.5 ± 5.4
Kt/V (single pool)1.5 ± 0.31.5 ± 0.3
nPCR or nPNA (g/kg per d)1.0 ± 0.21.0 ± 0.2
Serum albumin (g/dl)c3.75 ± 0.413.74 ± 0.42
    creatinine (mg/dl)9.0 ± 3.39.5 ± 3.6
    TIBC (mg/dl)201 ± 42210 ± 44
    ferritin (ng/ml)508 (305)445 (284)
    iron (ng/ml)61 ± 2664 ± 30
    iron saturation ratio (%)c30 ± 1230 ± 13
    bicarbonate (mEq/L)21.8 ± 2.822.1 ± 3.0
    phosphorus (mg/dl)b5.7 ± 1.55.7 ± 1.6
    calcium (mg/dl)c9.2 ± 0.79.2 ± 0.8
    intact PTH (pg/ml)c223 (135)229 (150)
Blood hemoglobin (g/dl)12.0 ± 1.312.3 ± 1.5
    WBC (×103/μl)7.3 ± 2.37.5 ± 2.5
    lymphocyte (% of total WBC count)21 ± 820 ± 7
Proportion received intravenous iron7112
  • a Count data are in percentage, and continuous values are in mean ± SD if normally distributed or median (interquartile range) if skewed. P < 0.001 for the difference between the two groups, unless otherwise specified. AV, arteriovenous; ESA, erythropoiesis-stimulating agent; PTH, parathyroid hormone; TIBC, total iron binding capacity; WBC, white blood cell.

  • b 0.05 > P > 0.001.

  • c P > 0.05.